Study ID: Alliance A081105
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Miroslaw Mazurczak, MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Active - Open to Accrual
For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.